Snake Venom Peptides in Medicine
Venom-Derived Peptides
6 FDA-approved drugs
At least six marketed medications trace their origins to snake venom peptides, including the ACE inhibitor captopril, prescribed to over 40 million people worldwide.
Frangieh et al., Molecules, 2021
Frangieh et al., Molecules, 2021
View as imageA Brazilian pit viper's bite kills through catastrophic blood pressure collapse. That same mechanism, isolated and refined, became captopril, the first ACE inhibitor, now one of the most prescribed drug classes in history. Snake venom peptides represent one of the most successful examples of turning a deadly natural substance into life-saving medicine. Six snake venom-derived drugs are currently on the market, and dozens more peptides are in various stages of research for cancer, antibiotic-resistant infections, kidney disease, and neurodegeneration.[1] This article covers what has already made it to pharmacy shelves, what is in the pipeline, and where the science runs into walls. For the broader landscape of animal-derived peptide therapeutics, see Amphibian Skin Peptides: The Pharmacy on a Frog's Back.
Key Takeaways
- Six snake venom-derived drugs are FDA-approved, including captopril (1981), eptifibatide, tirofiban, enalapril, batroxobin, and cobratide[1]
- Snake venoms contain at least 7 distinct cardiovascular peptide classes: PLA2, natriuretic peptides, bradykinin-potentiating peptides, CRISPs, disintegrins, fibrinolytic enzymes, and three-finger toxins[1]
- Researchers have identified more than 30 snake venom peptides with micromolar lytic activity against cancer cells, including both solid and liquid tumors[2]
- A snake toxin derivative showed efficacy for hyponatremia and polycystic kidney disease in a 2025 preclinical study in the Journal of the American Society of Nephrology[7]
- Peptide fractions from Bothrops jararaca venom demonstrated neuroprotective effects against oxidative stress in zebrafish models[8]
- Most snake venom anticancer peptides remain stuck at the in vitro stage, with the majority failing to progress even to preclinical animal testing[2]
The Captopril Origin Story: From Viper Venom to Blockbuster Drug
The discovery that turned snake venom into mainstream medicine began in 1949, when Brazilian pharmacologist Mauricio Rocha e Silva identified bradykinin while studying the effects of Bothrops jararaca envenomation. In the 1960s, his student Sergio Ferreira isolated bradykinin-potentiating peptides (BPPs) from the same viper's venom and brought samples to John Vane's laboratory in London.
BPPs work by inhibiting angiotensin-converting enzyme (ACE), the enzyme that converts angiotensin I to the vasoconstrictor angiotensin II. At Squibb Pharmaceuticals, Miguel Ondetti and David Cushman used the structure of these venom peptides as a template to synthesize captopril in 1975. The FDA approved it in 1981 for hypertension. Vane received the Nobel Prize in 1982 for related prostaglandin research, and captopril spawned an entire drug class: ACE inhibitors, now prescribed to tens of millions of people for hypertension, heart failure, and diabetic kidney disease.[1]
BPP-10c, one specific peptide from the original Bothrops venom, remains pharmacologically interesting. Unlike captopril (which only inhibits ACE), BPP-10c acts on both the renin-angiotensin system and the kinin-kallikrein system simultaneously, increasing bradykinin B2 receptor effects and boosting nitric oxide production.[3] This dual action suggests the original venom peptide may have pharmacological advantages that its synthetic offspring lost.
Beyond Captopril: The Six Approved Snake Venom Drugs
Captopril opened the door, but five other snake venom-derived drugs followed it to market:
Eptifibatide (Integrilin) is a cyclic heptapeptide derived from the disintegrin barbourin, found in southeastern pygmy rattlesnake (Sistrurus miliarius barbouri) venom. It blocks glycoprotein IIb/IIIa on platelets, preventing blood clot formation. Cardiologists use it during percutaneous coronary interventions to reduce the risk of acute cardiac ischemic events.[1]
Tirofiban (Aggrastat) works by the same mechanism as eptifibatide. It was modeled on the RGD (arginine-glycine-aspartate) motif found in disintegrins from saw-scaled viper (Echis carinatus) venom. Both drugs represented a new approach to anti-clotting therapy: instead of thinning the blood broadly, they target the specific receptor that platelets use to aggregate.[1]
Batroxobin is a serine protease from the lance-headed viper (Bothrops atrox) that selectively cleaves fibrinogen. It is used as a defibrinogenating agent in some countries for peripheral vascular disease and deep vein thrombosis.
Cobratide is a purified analgesic peptide from Chinese cobra (Naja atra) venom, approved in China for chronic pain conditions.
Enalapril, the second ACE inhibitor to reach market, refined captopril's structure to reduce side effects while maintaining the venom-inspired mechanism of ACE inhibition.
These six drugs share a common thread: all target the cardiovascular system. That reflects both where snake venom's biological effects are strongest (envenomation kills primarily through cardiovascular collapse) and where pharmaceutical investment has concentrated. The next generation of snake venom research aims much wider.
Seven Peptide Classes Targeting the Heart and Blood Vessels
Frangieh et al. (2021) cataloged at least seven distinct classes of cardiovascular-active molecules in snake venom, each with different mechanisms:[1]
| Peptide Class | Mechanism | Drug Example |
|---|---|---|
| Bradykinin-potentiating peptides (BPPs) | ACE inhibition, vasodilation | Captopril, enalapril |
| Disintegrins | Platelet aggregation inhibition via GPIIb/IIIa | Eptifibatide, tirofiban |
| Natriuretic peptides | Blood pressure reduction, diuresis | Lebetin 2 (preclinical) |
| Phospholipase A2 (PLA2) | Anti-inflammatory, cardioprotective | Preclinical |
| Three-finger toxins (3FTx) | Ion channel modulation | Cobratide |
| CRISPs | Smooth muscle relaxation | Preclinical |
| Fibrinolytic enzymes | Clot dissolution | Batroxobin |
Lebetin 2, a B-type natriuretic peptide isolated from Macrovipera lebetina venom, provided both immediate and prolonged protection against myocardial ischemia-reperfusion injury in animal models. It worked by modulating the post-ischemic inflammatory response, reducing the secondary damage that occurs when blood flow returns to heart tissue after a heart attack.[5] For more on natriuretic peptides in cardiac medicine, see Sacubitril/Valsartan: The Drug That Boosts Natriuretic Peptides.
Messadi (2023) expanded on the ischemic heart disease applications, noting that multiple venom components show cardioprotective activity through distinct pathways: anti-inflammatory, anti-apoptotic, and pro-angiogenic effects that promote new blood vessel formation in damaged heart tissue.[4]
Snake Venom Peptides Against Cancer: 30+ Candidates, Zero Approved Drugs
The anticancer pipeline from snake venom looks promising on paper and frustrating in practice. Almeida et al. (2025) identified more than 30 snake venom-derived peptides with micromolar lytic activity against different cancer cells, including both solid tumors (breast, lung, colon) and liquid tumors (leukemia).[2]
Three-finger toxins (3FTx) have attracted particular attention. These small, structurally stable peptides can disrupt cancer cell membranes, induce DNA damage, and target ion channels to halt cancer cell proliferation and trigger cell cycle arrest.[2]
Crotamine, a polypeptide from South American rattlesnake (Crotalus durissus terrificus) venom, has demonstrated selective toxicity toward certain cancer cell lines while sparing normal cells. It can also penetrate cell membranes, making it a potential delivery vehicle for other anticancer compounds.[6]
Perez-Peinado et al. (2020) highlighted that many snake venom peptides show dual antimicrobial and anticancer activity, working through a shared membrane-disrupting mechanism. Because cancer cells and bacterial cells both have membrane compositions that differ from healthy human cells, the same peptide can often target both.[6]
The problem is translation. Almeida et al. were blunt about this: transitioning from in vitro cell monolayer experiments to clinical settings "remains an unfulfilled goal, with the majority of studies failing to progress to more advanced stages, including the preclinical phase involving in vivo experiments."[2] The field has been generating anticancer candidates for decades without any reaching patients. The reasons are practical: venom peptides are often unstable in the bloodstream, difficult to manufacture at scale, and hard to deliver specifically to tumor sites.
Fighting Superbugs: Venom Peptides Against Antibiotic Resistance
Antibiotic resistance kills an estimated 1.27 million people annually, and snake venom peptides offer an alternative attack strategy. Muttiah and Hanafiah (2025) reviewed the antimicrobial arsenal within snake venom: metalloproteases, phospholipase A2 enzymes, three-finger toxins, L-amino acid oxidases, and dedicated antimicrobial peptides (AMPs).[9]
These compounds kill bacteria through mechanisms that are fundamentally different from conventional antibiotics. Rather than targeting a single bacterial enzyme (which bacteria can evolve resistance to), venom peptides typically disrupt entire cell membranes, generate oxidative stress, or inhibit biofilm formation. It is much harder for bacteria to develop resistance to physical membrane destruction than to evolve around a single enzyme inhibitor.[9]
Oguiura et al. (2021) specifically studied snake beta-defensins, a class of antimicrobial peptides found in snake venom that shares structural features with human defensins. These peptides showed broad-spectrum antibacterial activity in laboratory tests.[10] Tajbakhsh et al. (2018) took a different approach, producing a recombinant snake cathelicidin derivative in E. coli bacteria. The engineered peptide retained antibiofilm properties against drug-resistant bacteria, demonstrating that venom peptides can be manufactured using standard biotechnology methods.[11] For the broader landscape of antimicrobial peptides, see How Your Gut Bacteria Produce Antimicrobial Peptides and Antimicrobial Peptides in Wound Care.
Muttiah and Hanafiah also highlighted an emerging delivery approach: snake venom-derived extracellular vesicles (SVEVs), which are natural nanoparticles that protect venom toxins from degradation, improve bioavailability, and could facilitate targeted delivery of antimicrobial peptides.[9]
New Frontiers: Kidney Disease and Neuroprotection
The newest snake venom research moves well beyond the cardiovascular and antimicrobial applications that have dominated the field.
Stanajic-Petrovic et al. (2025) published a study in the Journal of the American Society of Nephrology describing a snake toxin derivative engineered for hyponatremia (dangerously low blood sodium) and autosomal dominant polycystic kidney disease (ADPKD). The derivative targets vasopressin V2 receptors, which regulate water reabsorption in the kidneys. Current treatments for ADPKD, such as tolvaptan, carry significant liver toxicity concerns. A venom-derived peptide targeting the same receptor through a different binding mechanism could offer a safer alternative.[7]
On the neurological front, da Cunha e Silva et al. (2025) demonstrated that peptide fractions from Bothrops jararaca venom, the same species that gave us captopril, protected zebrafish neurons against hydrogen peroxide-induced oxidative stress. At 10 micrograms per milliliter, the B. jararaca peptide fraction reversed oxidative stress-induced locomotor impairment after prolonged treatment, though a similar fraction from Daboia siamensis (Russell's viper) did not show the same effect. This species specificity suggests venom composition matters as much as the venom source.[8]
Lazarovici (2020) outlined the broader case for snake venom-derived neurotrophic factors, noting that certain venom proteins can promote nerve growth and survival through mechanisms distinct from existing neurotrophic drugs.[12]
Why Most Venom Peptides Never Become Drugs
The gap between "promising in the lab" and "available at the pharmacy" is enormous for snake venom peptides. Several factors explain why:
Stability. Most venom peptides evolved to work quickly at the bite site, not to circulate in the bloodstream for hours. They are rapidly broken down by proteases. Solutions include PEGylation (attaching polyethylene glycol chains), lipidation (adding fatty acid tails), and cyclization (connecting the peptide's ends into a ring), but each modification can alter the peptide's activity.
Selectivity. Venom is designed to kill. Isolating the therapeutically useful activity from the toxic activity requires careful molecular engineering. Three-finger toxins, for example, can simultaneously modulate ion channels (potentially useful for pain) and destroy cell membranes (potentially dangerous for normal tissue).
Manufacturing. Many venom peptides contain disulfide bonds and unusual amino acid modifications that make them expensive and difficult to synthesize at pharmaceutical scale. Recombinant production in bacteria, as Tajbakhsh et al. demonstrated with the snake cathelicidin, is one potential solution.[11]
The in vitro trap. As Almeida et al. documented, dozens of anticancer venom peptides show activity in cell culture dishes but never progress to animal models, let alone human trials.[2] Cell culture conditions are poor predictors of how a peptide will perform in a living body, where it faces enzymes, immune responses, and the challenge of reaching its target tissue.
The field is not without solutions. AI-driven drug design is being applied to venom peptide optimization, and modern delivery technologies (nanoparticles, hydrogels, microneedle patches) are being tested to overcome the stability and delivery barriers.[9] For more on how computational approaches are reshaping peptide development, see How AI Is Revolutionizing Peptide Drug Discovery. Related approaches using other venom sources are covered in Bee Venom Peptides: Melittin and Apamin in Research, Scorpion Venom Peptides: Chlorotoxin and Cancer Imaging, and Cone Snail Peptides (Conotoxins).
The Bottom Line
Snake venom peptides have already produced six approved drugs, most targeting cardiovascular disease, with captopril as the most commercially successful venom-derived medicine in history. The research pipeline extends to cancer (30+ peptides identified), antibiotic resistance, kidney disease, and neuroprotection. The central challenge remains translation: most venom peptides work in lab dishes but fail to reach animal models, let alone human patients. New approaches in peptide engineering, AI-driven optimization, and advanced delivery technologies may narrow this gap, but the field's track record since captopril suggests that the next venom-derived blockbuster will require both scientific innovation and sustained investment.